Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.

Authors:
Kim SH; Jo EJ; Mok J; Lee K; Kim KU and 4 more

Journal:
Korean J Intern Med

Publication Year: 2023

DOI:
10.3904/kjim.2022.361

PMCID:
PMC9993105

PMID:
36800677

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Korean J Intern Med

Abbreviation: Korean J Intern Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Internal Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Biomarkers of the relationship of particulate matter exposure with the progression of chronic respi…
Kim J; Chung SJ; Kim WJ. (2024) - Transparency Score: 3/6
Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in l…
Lee J; Lee DH; Park JE and 8 more (2024) - Transparency Score: 3/6
Long term management of people with post-tuberculosis lung disease.
Seo W; Kim HW; Kim JS and 1 more (2024) - Transparency Score: 3/6
New targets for type 2-low asthma.
Quoc QL; Choi Y; Hur GY and 1 more (2024) - Transparency Score: 3/6
Advanced heart failure: a contemporary approach.
Chun KH; Kang SM. (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"No potential conflict of interest relevant to this article was reported."

Evidence found in paper:

"This work was supported by a clinical research grant from the Pusan National University Hospital (2021)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025